Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968720 · ClinicalTrials.gov registry record · Phase 2
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 study of Dyslipidemias and Hypertriglyceridemia, sponsored by Catabasis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT01968720 is a Phase 2 study of Dyslipidemias and Hypertriglyceridemia that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 16 participants, below the 232-participant average among 28 other Dyslipidemias trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01968720, a Phase 2 study of Dyslipidemias and Hypertriglyceridemia, has completed, sponsored by Catabasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron triglyceride levels in patients with severe hypertriglyceridemia. This is a single-blind study. All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CAT-2003
Study Locations (4)
Florida
- - Miami
Indiana
- - Indianapolis
Maine
- - Auburn
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968720
The ClinicalTrials.gov registry entry for NCT01968720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 28 other Dyslipidemias trials with a reported enrollment target (93% lower). The listed sponsor is Catabasis Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Dyslipidemias appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01968720 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Indiana, Maine.
Frequently Asked Questions
What is clinical trial NCT01968720 about?
NCT01968720 is a clinical study titled "Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia". The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron trig...
What is the current status of trial NCT01968720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-10. Estimated completion is 2014-04.
What conditions does trial NCT01968720 study?
This clinical trial studies the following conditions: Dyslipidemias, Hypertriglyceridemia, Hyperlipidemias, Metabolic Diseases, Lipid Metabolism Disorders.
What interventions are being tested in trial NCT01968720?
The interventions under investigation include: Placebo (DRUG), CAT-2003 (DRUG).
Who is sponsoring clinical trial NCT01968720?
This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01968720 being conducted?
This trial has 4 study locations across Florida, Indiana, Maine, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Causal Mechanisms in Adolescent Arterial Stiffness
ACTIVE NOT RECRUITING · Phase 2
-
Study of ARO-APOC3 in Adults With Dyslipidemia
COMPLETED · Phase 2
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.